Seeking Alpha

Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
  • Update: Star Scientific - Let's Restate The Facts And Science: 4 comments
    Feb 8, 2013 2:47 PM | about stocks: RCPI

    Dr. John L. Faessel

    ON THE MARKET

    Commentary and Insights

    Update: Star Scientific (STSI) Nasdaq

    Let's restate the facts and science:

    1. Anatabine / Anatabloc is a potent, safe, non-addictive alpha-7 nicotinic receptor agonist that acts both on the CNS and immune system to suppress neurological and systemic inflammation.

    2. Anatabine / Anatabloc has been demonstrated to suppress many important biochemical markers associated with Alzheimer's and autoimmune disease in-vitro (i.e. in test tubes at the lab bench)

    3. Anatabine / Anatabloc has been demonstrated to ameliorate autoimmune thyroiditis (Hashimoto's disease) and biomarkers of Alzheimer's disease in cutting-edge animal models (i.e. in mice at the vivarium)

    4. Anatabine / Anatabloc has been demonstrated to suppress important biomarkers of inflammation and Hashimoto's disease in humans using rigorous, FDA approved, randomized, double-blinded, placebo-controlled studies (i.e. in the clinic). Anatabine / Anatabloc is clinically proven to significantly lower levels of anti-thyroid antibodies, improve thyroid volume and vascularization, and lower C-reactive protein (CRP) levels.

    5. Anatabine / Anatabloc is being evaluated by Star in at least two ongoing FDA approved clinical trials as treatments for Alzheimer's disease and rosacea.

    6. The clinical programs are run in collaboration with external key opinion leaders in the fields, including eminent endocrinologist and thyroid expert Dr. Paul Ladenson, and Dr. Michael Mullan of the Roskamp Institute, who is a recognized authority in Alzheimer's disease.

    Star Scientific has successfully advanced Anatabine / Anatabloc through a rigorous progression from lab bench through animal models and into the clinic with success at every stage, clear signals of efficacy in major disease areas, and no - absolutely no adverse events related to toxicity. All the scientific and clinical data indicates that the compound is safe, effective, and well tolerated.

    Four (4) peer-review papers have been published:

    1. "Anatabine lowers Alzheimer's Aβ production in vitro and in vivo" published in the European Journal of Pharmacology - 11/30/11
    www.sciencedirect.com/science/article/pii/S0014299911009836

    2) "Anatabine Ameliorates Experimental Autoimmune Thyroiditis" published in Endocrinology - Online 7/17/12, Print 9/1/12
    http://endo.endojournals.org/content/early/2012/07/17/en.2012-1452.abstract?rss=1

    3) "Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation" published in the European Journal of Pharmacology - 1/5/13
    www.sciencedirect.com/science/article/pii/S001429991200948X

    4) "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine" published in PLOS ONE - 1/30/13
    www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0055392

    Anatabine / Anatabloc is on the front burner of science

    The interest in alpha-7 nicotinic receptor agonists such as anatabine continues to grow, as reflected by an increasing number of clinical trials; a sampling of them can be seen on the U.S National Institutes of Health website clinicaltrials.gov here. Pharma is scrambling to find and secure intellectual property rights on alpha-7 nicotinic receptor agonists that are safe, effective, and well tolerated. Anatabine / Anatabloc is a safe, effective, and well-tolerated alpha-7 nicotinic acid receptor agonist that acts both on the CNS and immune system to suppress neurological and systemic inflammation.

    Anatabine has also been demonstrated to affect the JAK-STAT pathway by suppressing STAT3 phosphorylation, inhibits TNF-alpha and NF-kB levels in-vitro.

    And above all, anatabine / Anatabloc has recently demonstrated proof of concept and shown efficacy in the clinic in humans.

    In sum; by all indications, anatabine / Anatabloc appears to be the current gold standard in the field and adds a substantial multiplier in gauging its and the Star's potential and value.

    As of today Institutional Ownership is at a new high [2/8/2013]

    (Less than 5% holders)

    Total Number of Holders

    122

    % of Shares Outstanding

    20.85%

    Total Shares Held

    30,506,364

    Link Nasdaq detail here

     

    Disclosure: I am long STSI.

    Stocks: RCPI
Back To Dr. John Faessel's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (4)
Track new comments
  • adamfeuerstein
    , contributor
    Comments (322) | Send Message
     
    John -- How come you're not pimping the Johns Hopkins relationship any longer? And what happened to your Jan. 14th column? Was it disappeared?
    8 Feb 2013, 04:58 PM Reply Like
  • Mike Lawson
    , contributor
    Comments (11) | Send Message
     
    Adam F., as you know, this is an excerpt from the press release, early this year, about the human study the “ASAP thyroid study”

     

    “Dr. Paul Ladenson, senior endocrinological consultant for the study, stated, "Data from this rigorously conducted, placebo-controlled, double blind trial show that anatabine-treated subjects had progressive decreases in circulating thyroglobulin antibody levels, which became significant by the end of the trial. Current treatment for autoimmune thyroiditis is limited to end-stage disease when irreversible gland damage necessitates lifelong thyroid hormone replacement. The prospect of a novel nutritional or pharmaceutical intervention that could preserve thyroid health represents an encouraging advance. Further clinical studies are now warranted." “

     

    I've been told that thyroid researchers stop and listen whenever Paul W. Ladenson, MD puts anything on the record.

     

    Dr Ladenson has a resume that would fill a book but I think the following press release from last September is pointed and succinct.

     

    The American THYROID Association

     

    Falls Church, Virginia. Sep. 19, 2012 The American THYROID Association (ATA) today announced today announced it will honor Paul W. Ladenson, MD, of Johns Hopkins University in Baltimore, with the 2012 Lewis E. Braverman Award on Sept. 21 at the 82nd ATA Annual Meeting in Québec City, Québec, Canada. The Lewis E. Braverman Lectureship Award recognizes a member of the ATA who has demonstrated excellence and passion for mentoring fellows, students, and junior faculty and has a long history of productive THYROID research.

     

    “While advancing his own body of research, Dr. Ladenson has become widely respected as one of endocrinology’s most thoughtful and trusted mentors, making him an outstanding choice for the 2012 Lewis E. Braverman Lectureship Award,” said ATA President James A. Fagin, MD, of Memorial Sloan-Kettering Cancer Center. “Countless fellows and trainees have benefited from the opportunity to work directly with Dr. Ladenson over the years and have gone on to assume leadership positions in the field of endocrinology at various universities, research institutes, and within the ATA.”

     

    Dr. Ladenson holds several distinguished positions at Johns Hopkins University, where he is the John Eager Howard Professor of Endocrinology, and Professor of Medicine, Pathology, Oncology, Radiology and Radiological Science. He is also director of the Division of Endocrinology and Metabolism and a Distinguished University Professor.

     

    Dr. Ladenson’s research interests include applications of THYROID hormone analogues for treatment of cardiovascular disease, novel approaches to THYROID cancer diagnosis and management, and health economic analyses related to THYROID patient care. Currently, Dr. Ladenson is investigating effects of the nutritional supplement anatabine on autoimmune thyroiditis.
    8 Feb 2013, 05:41 PM Reply Like
  • bisom08
    , contributor
    Comments (10) | Send Message
     
    Pretty sad to see Adam Fraudstein trolling Seeking Alpha looking for any opportunity to spew a little snarky slop.

     

    How ironic to see Fraudstein using the word "pimp" in any context.

     

    What a pathetic organization The Street has become.
    10 Feb 2013, 10:24 AM Reply Like
  • David Calleo
    , contributor
    Comments (76) | Send Message
     
    We are just looking for some numbers? Why cannot that be said, subject to peer review.? That is why Wall Street hammered this. The peer review can take 30-40 weeks. SO do not count on this being fast and furious. If this was as good as you claim, there would be thousands of people posting results, news people would be on it and so would the doctors that have heard of this and used it themselves. I think Jonnie is milking this last deal of his lifetime. What about Mr. Sharp, no good news there?
    9 Feb 2013, 08:11 PM Reply Like
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.